盐酸伊伐布雷定在慢性心力衰竭血液透析患者中的疗效和安全性。

The efficacy and safety of ivabradine hydrochloride in hemodialysis patients with chronic heart failure.

机构信息

Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

Akihabara Kidney Clinic, Tokyo, Japan.

出版信息

Ther Apher Dial. 2024 Jun;28(3):354-363. doi: 10.1111/1744-9987.14107. Epub 2024 Jan 10.

DOI:10.1111/1744-9987.14107

PMID:38199237

Abstract

INTRODUCTION

There is little evidence for ivabradine hydrochloride in patients undergoing hemodialysis.

METHODS

In this open-label prospective interventional trial of hemodialysis patients with chronic heart failure, during 12 weeks of treatment, changes in Heart rate (HR), frequency of dialysis-related hypotension were examined, and we investigated health-related quality of life (HR-QOL) and adverse effects.

RESULTS

18 patients from 6 facilities were enrolled in the study. HR significantly decreased over time, from 87 ± 12.61/min at baseline to 75.85 ± 8.91/min (p = 0.0003), and systolic blood pressure also increased significantly (p < 0.0001). The frequency of dialysis-related hypotension was markedly reduced (p = 0.0001). The HR-QOL survey showed significant improvements in Social Functioning among others (p = 0.0178). No specific adverse events occurred.

CONCLUSION

Ivabradine hydrochloride improved dialysis-related hypotension. Furthermore, the HR-QOL improvement effect were suggested. These results demonstrated the safety and effectiveness of ivabradine hydrochloride.

摘要

简介

盐酸伊伐布雷定在接受血液透析的患者中应用的证据较少。

方法

在这项针对慢性心力衰竭血液透析患者的开放性前瞻性干预试验中，在 12 周的治疗期间，观察了心率（HR）的变化、与透析相关的低血压的发生频率，并研究了健康相关生活质量（HR-QOL）和不良反应。

结果

研究共纳入了来自 6 家机构的 18 名患者。HR 随时间显著降低，从基线时的 87±12.61/min 降至 75.85±8.91/min（p=0.0003），收缩压也显著升高（p<0.0001）。与透析相关的低血压发生频率显著降低（p=0.0001）。HR-QOL 调查显示社会功能等方面有显著改善（p=0.0178）。未发生特定的不良反应事件。